Stockscreener 앱 받기
0.00
100.00%
-0.2075
Casi Pharmaceuticals Inc 주식(CASI)의 최신 뉴스
[Form 3] CASI Pharmaceuticals, Inc. Initial Statement of Beneficial Ownership - Stock Titan
CASI Pharmaceuticals (CASIF) CMO holds 116,333 fully vested options at $1.93 - Stock Titan
CASIF: CASI Pharmaceuticals Inc.Comparison to Industry - Zacks Investment Research
All News for CASIF : CASI Pharmaceuticals Inc. - Zacks Investment Research
CASI SEC FilingsCasi Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
CASI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Aug Wrap: Can CASI Pharmaceuticals Inc maintain its current growth rate2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Why Is CASI Pharmaceuticals, Inc. (CASIF) Stock Down Today? - Meyka
Aug Shorts: Whats the profit margin of CASI Pharmaceuticals IncPortfolio Value Report & Capital Efficient Trade Techniques - baoquankhu1.vn
Diluted net income available to common stockholders of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI (NASDAQ: CASI) director lists fully vested stock options on Form 3 - stocktitan.net
Director Alex Wu details CASI (CASIF) vested stock options and shares - Stock Titan
What is the current Price Target and Forecast for CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research
Wei-Wu He and ETP funds update CASI Pharmaceuticals (CASI) 53% stake - Stock Titan
CASI Pharmaceuticals to be delisted from Nasdaq, shares to move to OTC market - MSN
CASI (NASDAQ: CASI) director He Wei-Wu details share and option stakes - Stock Titan
CASI Pharmaceuticals (CASI) director James Huang reports initial holdings - Stock Titan
What is the long term forecast for CASI Pharmaceuticals Inc stockEarnings Recap Report & Accurate Buy Signal Alerts - baoquankhu1.vn
CASI PHARMACEUTICALS TO REPORT SECOND QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL AUGUST 12, 2022 - Quantisnow
CASI PHARMACEUTICALS TO REPORT FIRST QUARTER 2022 FINANCIAL RESULTS AND HOST CONFERENCE CALL MAY 12, 2022 - Quantisnow
Total assets of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Short Squeeze: Can CASI Pharmaceuticals Inc deliver consistent EPS growth2025 Valuation Update & Daily Stock Momentum Reports - baoquankhu1.vn
Why Did CASI Stock Plummet 64% Today To Hit An All-Time Low? - Stocktwits
CASI Pharmaceuticals Inc. (CASIF) Price To Cash Flow - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Liabilities - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Return On Equity (TTM) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Long Term Debt (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Enterprise Value - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Expenses (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Book Value - Zacks Investment Research
CASI PHARMACEUTICALS INC (CASIF.US) Income Statements, Balance Sheet & Cashflow - Longbridge
CASI PHARMACEUTICALS INC (CASIF.US) Latest News & Headlines - Longbridge
CASI Pharmaceuticals, Inc.: Financial Data Forecasts Estimates and Expectations | CASIF | KYG1933S1012 - marketscreener.com
CASI Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | CASIF | KYG1933S1012 - marketscreener.com
CASI Pharmaceuticals, Inc.: Revenue and Earnings Analysts Forecasts Revisions | CASIF | KYG1933S1012 - marketscreener.com
Casi Pharmaceuticals CEO David Cory to step down at end of March - Investing.com
CASI Pharmaceuticals CEO David Cory to Step Down; Executive Chairman Wei-Wu He Assumes Top Role - TipRanks
Leadership change at CASI Pharmaceuticals (NASDAQ: CASI) as CEO exits - Stock Titan
CASI Pharmaceuticals Inc. (CASIF) Debt Equity Ratio (Quarterly) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Price Book Value - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Cash From Operations (TTM) - Zacks Investment Research
CASIF (CASI Pharmaceuticals) PB Ratio : (As of Mar. 02, 2026) - GuruFocus
CASI Pharmaceuticals Inc. (CASIF) Return On Assets (TTM) - Zacks Investment Research
Net debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI Pharmaceuticals Inc. (CASIF) Earnings Yield (TTM) - Zacks Investment Research
EBIT per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBITDA per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBITDA margin % of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
After tax other income/expense of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Long term debt to total equity ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Operating expenses (excl. COGS) of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CapEx per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Net current asset value per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Preferred dividends of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Enterprise value to EBITDA ratio of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Working capital per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Total debt of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Free cash flow per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Total debt per share of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
CASI Pharmaceuticals, Inc. Balance Sheet – OTC:CASIF - TradingView
Technical Analysis of CASI Pharmaceuticals, Inc. (OTC:CASIF) - TradingView
CASI Pharmaceuticals Inc. (CASIF) Revenue (Quarterly) Yoy Growth - Zacks Investment Research
CASI Pharmaceuticals Inc. (CASIF) Total Expenses (TTM) - Zacks Investment Research
Diluted shares outstanding of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
Gross profit of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
EBIT of CASI Pharmaceuticals, Inc. – OTC:CASIF - TradingView
0.49%
1.47%
자본화:
|
볼륨(24시간):